Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone Adaption to chronic human diarrheal diseases
Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone Adaption to chronic human diarrheal diseases
复制标题
DOI：
10.4161/viru.2.2.15647
复制
发表时间：
2011-03-01
期刊：
影响因子：
5.2
通讯作者：
Click, Robert E.
中科院分区：
文献类型：
--
作者：
Click, Robert E.
一种自然发生的胃肠道疾病，主要发生在反刍动物身上（约翰病），是一种由鸟分枝杆菌亚种副结核（MAP）引起的慢性衰弱性疾病。MAP感染主要发生在子宫内和新生儿。在我们的Dietzia益生菌治疗之外，没有预防/治疗牛副结核病的治疗方法。有趣的是，MAP在克罗恩病（CD）中的作用以及最近在糖尿病、溃疡性结肠炎和肠易激综合征（IBS）中的作用一直处于争议的中心；后两者，如乳糜泻，被认为是慢性肠道炎症的结果。治疗，无论是传统的还是生物制剂，诱导和维持缓解的目的都是为了减少炎症的一个复杂部分。大多数具有不同程度的副作用，失去治疗价值，更重要的是，没有常规的预防和/或治疗效果。基于(a)约翰病和克罗恩病的相似性，(b) Dietzia在特定培养条件下抑制MAP生长的报告，以及(c) Dietzia作为益生菌使用时的发现，(i)对成年牛副结核有治疗作用，（ii）防止MAP感染小牛的疾病发展，本研究的目标是设计适用于IBD患者的方案。发现Dietzia对所有年龄的牛以及正常和免疫缺陷小鼠都是安全的。结果强烈支持临床评价作为益生菌，联合/不联合地塞米松。
A naturally occurring gastrointestinal disease, primarily of ruminants (Johne disease), is a chronic debilitating disease that is caused by Mycobacterium avium subspecies paratuberculosis (MAP). MAP infection occurs primarily in utero and in newborns. Outside our Dietzia probiotic treatment, there are no preventive/curative therapies for bovine paratuberculosis. Interestingly, MAP is at the center of controversy as to its role in (cause of) Crohn disease (CD) and more recently, its role in diabetes, ulcerative colitis, and irritable bowel syndrome (IBS); the latter two, like CD, are considered to be a result of chronic intestinal inflammation. Treatments, both conventional and biologic agents, which induce and maintain remission are directed at curtailing processes that are an intricate part of inflammation. Most possess side effects of varying severity, lose therapeutic value, and more importantly, none routinely result in prevention and/or cures. Based on (a) similarities of Johne disease and Crohn disease, (b) a report that Dietzia inhibited growth of MAP under specific culture conditions, and (c) findings that Dietzia when used as a probiotic, (i) was therapeutic for adult bovine paratuberculosis, and (ii) prevented development of disease in MAP-infected calves, the goal of the present investigations was to design protocols that have applicability for IBD patients. Dietzia was found safe for cattle of all ages and for normal and immunodeficient mice. The results strongly warrant clinical evaluation as a probiotic, in combination with/without dexamethasone.